1
|
Torres‐Sauret Q, Vilchis‐Reyes MA, Martínez R, Romero‐Ceronio N, Alarcon‐Matus E, Hernández‐Abreu O, Vázquez Cancino R, Alvarado Sánchez. C. Crossing borders: On‐Water Synthesis of Flavanones. ChemistrySelect 2022. [DOI: 10.1002/slct.202202567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Affiliation(s)
- Quirino Torres‐Sauret
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Miguel A. Vilchis‐Reyes
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Roberto Martínez
- Instituto de Química Universidad Nacional Autónoma de México Circuito exterior s/n Ciudad Universitaria, Alcaldía Coyoacán CP 04510 Ciudad de México México
| | - Nancy Romero‐Ceronio
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Erika Alarcon‐Matus
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Oswaldo Hernández‐Abreu
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Romario Vázquez Cancino
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| | - Cuauhtémoc Alvarado Sánchez.
- Centro de Investigación en Ciencia y Tecnología Aplicada de Tabasco (CICTAT), División Académica de Ciencias Básicas Universidad Juárez Autónoma de Tabasco Carretera Cunduacán-Jalpa Km 1, Col. La Esperanza 86690. Cunduacán Tabasco México
| |
Collapse
|
2
|
Escher I, Hahn M, A. Ferrero G, Adelhelm P. A Practical Guide for Using Electrochemical Dilatometry as Operando Tool in Battery and Supercapacitor Research. ENERGY TECHNOLOGY (WEINHEIM, GERMANY) 2022; 10:2101120. [PMID: 35859916 PMCID: PMC9285449 DOI: 10.1002/ente.202101120] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 02/18/2022] [Indexed: 06/15/2023]
Abstract
Lithium-ion batteries and related battery concepts show an expansion and shrinkage ("breathing") of the electrodes during cell cycling. The dimensional changes of an individual electrode or a complete cell can be continuously measured by electrochemical dilatometry (ECD). The obtained data provides information on the electrode/cell reaction itself but can be also used to study side reactions or other relevant aspects, e.g., how the breathing is influenced by the electrode binder and porosity. The method spans over a wide measurement range and allows the determination of macroscopic as well as nanoscopic changes. It has also been applied to supercapacitors. The method has been developed already in the 1970s but recent advancements and the availability of commercial setups have led to an increasing interest in ECD. At the same time, there is no "best practice" on how to evaluate the data and several pitfalls exist that can complicate the comparison of literature data. This review highlights the recent development and future trends of ECD and its use in battery and supercapacitor research. A practical guide on how to evaluate the data is provided along with a discussion on various factors that influence the measurement results.
Collapse
Affiliation(s)
- Ines Escher
- Institut für ChemieHumboldt Universität zu Berlin12489BerlinGermany
| | | | | | - Philipp Adelhelm
- Institut für ChemieHumboldt Universität zu Berlin12489BerlinGermany
- Helmholtz-Zentrum BerlinJoint Research Group Operando Battery Analysis (CE-GOBA)14109BerlinGermany
| |
Collapse
|
3
|
Lee JY, Shin YS, Jeon S, Lee SI, Cho J, Myung S, Jang MS, Kim S, Song JH, Kim HR, Park CM. Synthesis and biological evaluation of
2‐benzylaminoquinazolin
‐4(
3
H
)‐one derivatives as a potential treatment for
SARS‐CoV
‐2. B KOREAN CHEM SOC 2022; 43:412-416. [PMID: 35440837 PMCID: PMC9011860 DOI: 10.1002/bkcs.12470] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 12/21/2021] [Accepted: 12/22/2021] [Indexed: 12/13/2022]
Abstract
Despite the continuing global crisis caused by coronavirus disease 2019 (COVID‐19), there is still no effective treatment. Therefore, we designed and synthesized a novel series of 2‐benzylaminoquinazolin‐4(3H)‐one derivatives and demonstrated that they are effective against SARS‐CoV‐2. Among the synthesized derivatives, 7‐chloro‐2‐(((4‐chlorophenyl)(phenyl)methyl)amino)quinazolin‐4(3H)‐one (Compound 39) showed highest anti‐SARS‐CoV‐2 activity, with a half‐maximal inhibitory concentration value greater than that of remdesivir (IC50 = 4.2 μM vs. 7.6 μM, respectively), which gained urgent approval from the U.S. Food and Drug Administration. In addition, Compound 39 showed good results in various assays measuring metabolic stability, human ether a‐go‐go, Cytochromes P450 (CYPs) inhibition, and plasma protein binding (PPB), and showed better solubility and pharmacokinetics than our previous work.
Collapse
Affiliation(s)
- Jun Young Lee
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Young Sup Shin
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Sangeun Jeon
- Zoonotic Virus Laboratory Institut Pasteur Korea Seongnam‐si Gyeonggi‐do South Korea
| | - Se In Lee
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Jung‐Eun Cho
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Subeen Myung
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
- Medicinal Chemistry and Pharmacology Korea University of Science and Technology Daejeon South Korea
| | - Min Seong Jang
- Department of Non‐Clinical Studies Korea Institute of Toxicology Yuseong‐gu, Daejeon South Korea
| | - Seungtaek Kim
- Zoonotic Virus Laboratory Institut Pasteur Korea Seongnam‐si Gyeonggi‐do South Korea
| | - Jong Hwan Song
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Hyoung Rae Kim
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
| | - Chul Min Park
- Center for Convergent Research of Emerging Virus Infection (CEVI) Korea Research Institute of Chemical Technology Yuseong‐gu, Daejeon South Korea
- Medicinal Chemistry and Pharmacology Korea University of Science and Technology Daejeon South Korea
| |
Collapse
|
4
|
Sun ZG, Li ZN, Zhang JM, Hou XY, Yeh SM, Ming X. Recent Development of Flavonoids with Various Activities. Curr Top Med Chem 2022; 22:305-329. [PMID: 35040404 DOI: 10.2174/1568026622666220117111858] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2021] [Revised: 12/24/2021] [Accepted: 12/27/2021] [Indexed: 11/22/2022]
Abstract
Flavonoids, a series of compounds with C6-C3-C6 structure, mostly originate from plant metabolism. Flavonoids have shown beneficial effects on many aspects of human physiology and health. Recently, many flavonoids with various activities have been discovered, which has led to more and more studies focusing on their physiological and pharmacodynamic activities. The anti-cancer and anti-viral activities especially have attracted the attention of many researchers. Therefore, the discovery and development of flavonoids as anti-disease drugs has great potential and may make significant contribution to fighting diseases. This review focus on the discovery and development of flavonoids in medicinal chemistry in recent years.
Collapse
Affiliation(s)
- Zhi-Gang Sun
- Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, China
- Departments of Cancer Biology and Biomedical Engineering, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
| | - Zhi-Na Li
- Central Laboratory, Linyi Central Hospital, No.17 Jiankang Road, Linyi 276400, China
| | - Jin-Mai Zhang
- Room 205, BIO-X white house, Shanghai Jiao Tong University, No.1954 Huashan Road, Shanghai 200030, P.R. China
| | - Xiao-Yan Hou
- Qilu Pharmaceutical Co., Ltd, 8888 Lvyou Road, High-tech Zone, Jinan, 250104, P.R. China
| | - Stacy Mary Yeh
- Departments of Cancer Biology and Biomedical Engineering, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
| | - Xin Ming
- Departments of Cancer Biology and Biomedical Engineering, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
| |
Collapse
|
5
|
Lu T, Li Y, Lu W, Spitters TWGM, Fang X, Wang J, Cai S, Gao J, Zhou Y, Duan Z, Xiong H, Liu L, Li Q, Jiang H, Chen K, Zhou H, Lin H, Feng H, Zhou B, Antos CL, Luo C. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3. Acta Pharm Sin B 2021; 11:3206-3219. [PMID: 34729310 PMCID: PMC8546857 DOI: 10.1016/j.apsb.2021.04.015] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/08/2021] [Accepted: 04/20/2021] [Indexed: 12/13/2022] Open
Abstract
The TEA domain (TEAD) family proteins (TEAD1‒4) are essential transcription factors that control cell differentiation and organ size in the Hippo pathway. Although the sequences and structures of TEAD family proteins are highly conserved, each TEAD isoform has unique physiological and pathological functions. Therefore, the development and discovery of subtype selective inhibitors for TEAD protein will provide important chemical probes for the TEAD-related function studies in development and diseases. Here, we identified a novel TEAD1/3 covalent inhibitor (DC-TEADin1072) with biochemical IC50 values of 0.61 ± 0.02 and 0.58 ± 0.12 μmol/L against TEAD1 and TEAD3, respectively. Further chemical optimization based on DC-TEAD in 1072 yielded a selective TEAD3 inhibitor DC-TEAD3in03 with the IC50 value of 0.16 ± 0.03 μmol/L, which shows 100-fold selectivity over other TEAD isoforms in activity-based protein profiling (ABPP) assays. In cells, DC-TEAD3in03 showed selective inhibitory effect on TEAD3 in GAL4-TEAD (1–4) reporter assays with the IC50 value of 1.15 μmol/L. When administered to zebrafish juveniles, experiments showed that DC-TEAD3in03 reduced the growth rate of zebrafish caudal fins, indicating the importance of TEAD3 activity in controlling proportional growth of vertebrate appendages.
Collapse
|
6
|
Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021; 25:1315-1360. [PMID: 33844136 PMCID: PMC8040371 DOI: 10.1007/s11030-021-10217-3] [Citation(s) in RCA: 253] [Impact Index Per Article: 84.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 03/22/2021] [Indexed: 02/06/2023]
Abstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Collapse
Affiliation(s)
- Rohan Gupta
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Devesh Srivastava
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Mehar Sahu
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Swati Tiwari
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Rashmi K Ambasta
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India
| | - Pravir Kumar
- Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India.
| |
Collapse
|
7
|
Lee JY, Shin YS, Jeon S, Lee SI, Noh S, Cho JE, Jang MS, Kim S, Song JH, Kim HR, Park CM. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments. Bioorg Med Chem Lett 2021; 39:127885. [PMID: 33662537 PMCID: PMC7920804 DOI: 10.1016/j.bmcl.2021.127885] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Revised: 02/08/2021] [Accepted: 02/10/2021] [Indexed: 12/13/2022]
Abstract
Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 < 0.25 μM) and anti-MERS-CoV activities (IC50 < 1.1 μM) with no cytotoxicity (CC50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.
Collapse
Affiliation(s)
- Jun Young Lee
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Young Sup Shin
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Sangeun Jeon
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea
| | - Se In Lee
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Soojin Noh
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Jung-Eun Cho
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Min Seong Jang
- Department of Non-Clinical Studies, Korea Institute of Toxicology, Yuseong-gu, Daejeon 34114, South Korea
| | - Seungtaek Kim
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea
| | - Jong Hwan Song
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Hyoung Rae Kim
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Chul Min Park
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; Korea University of Science and Technology, Daejeon 34114, South Korea.
| |
Collapse
|
8
|
Lee JY, Shin YS, Lee J, Kwon S, Jin YH, Jang MS, Kim S, Song JH, Kim HR, Park CM. Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors. Bioorg Med Chem Lett 2020; 30:127472. [PMID: 32781216 PMCID: PMC7414322 DOI: 10.1016/j.bmcl.2020.127472] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 07/27/2020] [Accepted: 08/04/2020] [Indexed: 10/26/2022]
Abstract
New therapies for treating coronaviruses are urgently needed. A series of 4-anilino-6-aminoquinazoline derivatives were synthesized and evaluated to show high anti-MERS-CoV activities. N4-(3-Chloro-4-fluorophenyl)-N6-(3-methoxybenzyl)quinazoline-4,6-diamine (1) has been identified in a random screen as a hit compound for inhibiting MERS-CoV infection. Throughout optimization process, compound 20 was found to exhibit high inhibitory effect (IC50 = 0.157 μM, SI = 25) with no cytotoxicity and moderate in vivo PK properties.
Collapse
Affiliation(s)
- Jun Young Lee
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Young Sup Shin
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Jihye Lee
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea
| | - Sunoh Kwon
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, South Korea
| | - Young-Hee Jin
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; KM Application Center, Korea Institute of Oriental Medicine, Dong-gu, Daegu 41062, South Korea
| | - Min Seong Jang
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea; Department of Non-Clinical Studies, Korea Institute of Toxicology, Yuseong-gu, Daejeon 34114, South Korea
| | - Seungtaek Kim
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do 13488, South Korea
| | - Jong Hwan Song
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Hyoung Rae Kim
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea
| | - Chul Min Park
- Center for Convergent Research of Emerging Virus Infection (CEVI), Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea.
| |
Collapse
|